FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Mahoney Stephen F.						2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]							of Reporting P cable) or (give title	Person(s) to Iss 10% O Other (	wner
(Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET					3. Date of Earliest Transaction (Month/Day/Year) 09/20/2018							X Officer below)		below)	,
(Street) HAMILTON D0 HM11				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							S. Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person			
(City)	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)  Table II - Derivati					2A. Deemed Execution Date, if any (Month/Day/Year			3. Transactic Code (Ins 8) Code V	4. Securion Disposed 5)  Amount	tities Acquired (A) or d Of (D) (Instr. 3, 4 and (A) or (D) Price		5. Amour Securitie Beneficia Owned Reported Transact (Instr. 3 a	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction arrivative Conversion Curity or Exercise (Month/Day/Year) 3A. Deemed Execution Date, if any			4. Transa	4. 5. Number of Code (Instr. Derivativ			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction( (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option	\$30.93	09/20/2018		Code	v	(A) 50,000	(D)	Exercisable (1)	Date 09/19/2028	Class A Common Shares	Shares 50,000	\$0	50,000	D	

## **Explanation of Responses:**

1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018.

/s/ Thomas W. Beetham, Attorney-in-Fact For Stephen F. 09/24/2018

**Mahoney** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.